-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, J26dLB5X+942zO3ztxhfGH0AxvtqLlIEna5W4uAcJsJfMk20gIW2DteX87YljK4l ++FBUUbOLUYoselm/2Kg7Q== 0000893220-07-000549.txt : 20070301 0000893220-07-000549.hdr.sgml : 20070301 20070301170654 ACCESSION NUMBER: 0000893220-07-000549 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061231 FILED AS OF DATE: 20070301 DATE AS OF CHANGE: 20070301 EFFECTIVENESS DATE: 20070301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PAR PHARMACEUTICAL COMPANIES, INC. CENTRAL INDEX KEY: 0000878088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223122182 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10827 FILM NUMBER: 07664470 BUSINESS ADDRESS: STREET 1: 300 TICE BOULEVARD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 845-425-7100 MAIL ADDRESS: STREET 1: 300 TICE BOULEVARD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: PHARMACEUTICAL RESOURCES INC DATE OF NAME CHANGE: 19940526 NT 10-K 1 w31174ntnt10vk.htm NT 10-K nt10vk
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
                 
(Check One):
  þ Form 10-K   o Form 20-F   o Form 11-K   o Form 10-Q
 
  o Form 10-D   o Form N-SAR   o Form N-CSR    
     For Period Ended: December 31, 2006     
     o Transition Report on Form 10-K
     o Transition Report on Form 20-F
     o Transition Report on Form 11-K
     o Transition Report on Form 10-Q
     o Transition Report on Form N-SAR
     For the Transition Period Ended: ___________________________
     Read Instruction (on back page) Before Preparing Form. Please print or type.
     Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
     If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:_____________________
PART I — REGISTRANT INFORMATION
Par Pharmaceutical Companies, Inc.
Full Name of Registrant
300 Tice Boulevard
Address of Principal Executive Office (Street and Number)
Woodcliff Lake, New Jersey 07677
City, State and Zip Code

 

 

PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)
    (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 
o   (b) The subject annual report, semi-annual report, transition report on Form 10- K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Necessary)
On July 5, 2006, Par Pharmaceutical Companies, Inc. (the “Company”) announced that, due to accounting errors, certain financial information included in the Company’s Annual Reports on Form 10-K for the years ended December 31, 2004 and December 31, 2005, and on the Company’s Quarterly Report on Form 10-Q for the first quarter of 2006, needed to be restated (the “Restatement”). The Company will soon file its amended 10-K for the year ended December 31, 2005, but is still in the process of preparing restated financial statements for the first quarter of 2006 and preparing financial statements for the second and third quarters of 2006. Due to the Company’s continuing efforts with respect to the Restatement and preparation of its second and third quarter financial statements, the Company is not able to finalize the financial statements and related information for inclusion in its Annual Report on Form 10-K for the year ended December 31, 2006. Accordingly, the Company is unable to file its Annual Report on Form 10-K for the year ended December 31, 2006 within the prescribed time period. The Company is working diligently to review and finalize the financial information so that it can become current with its reporting obligations and intends to file its Annual Report on Form 10-K for the year ended December 31, 2006 as soon as practicable.
PART IV — OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification:
Gerard A. Martino, Executive Vice President and Chief Financial Officer, (201) 802-4000
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes o No x*

 

 

* The Registrant’s Quarterly Report on Form 10-Q for the quarter ended July 1, 2006 was filed without Part I, Items 1 and 2, and the Rule 13a-14(a) and Section 906 certifications by its President and Chief Executive Officer and its Chief Financial Officer, as indicated therein and in the Registrant’s Notification of Late Filing on Form 12b-25, filed with the Commission on August 11, 2006. The Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 was filed without Part I, Items 1 and 2, and the Rule 13a-14(a) and Section 906 certifications by its President and Chief Executive Officer and its Chief Financial Officer, as indicated therein and in the Registrant’s Notification of Late Filing on Form 12b-25/A, filed with the Commission on December 21, 2006.
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes x No o
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
The Company is not in a position to determine whether there will be significant changes between the results of operations for the year ended December 31, 2005 and the year ended December 31, 2006 because the Company’s unaudited financial statements for each of the quarters of 2006 and the audited financial statements for the year ended December 31, 2006 are not yet complete due to the Company’s work on the Restatement.
Par Pharmaceutical Companies, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
         
     
Date: March 1, 2007  /s/ Thomas J. Haughey    
  By: Thomas J. Haughey   
  Title:   Executive Vice President — General Counsel   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----